These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27020644)

  • 1. A Roadmap for the Implementation of Continued Process Verification.
    Boyer M; Gampfer J; Zamamiri A; Payne R
    PDA J Pharm Sci Technol; 2016; 70(3):282-92. PubMed ID: 27020644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA 2011 process validation guidance: lifecycle compliance model.
    Campbell C
    PDA J Pharm Sci Technol; 2014; 68(2):185-91. PubMed ID: 24668605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing.
    Jiang M; Severson KA; Love JC; Madden H; Swann P; Zang L; Braatz RD
    Biotechnol Bioeng; 2017 Nov; 114(11):2445-2456. PubMed ID: 28710854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of benchmarking in the development of biopharmaceutical products.
    Giffin M; McLeish S
    Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate specifications at the IND stage.
    Geigert J
    Dev Biol Stand; 1997; 91():39-43. PubMed ID: 9413681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality.
    O'Connor TF; Yu LX; Lee SL
    Int J Pharm; 2016 Jul; 509(1-2):492-498. PubMed ID: 27260134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing Product Confidence-Shifting Paradigms.
    Phillips M; Kashyap V; Cheung MS
    PDA J Pharm Sci Technol; 2015; 69(6):736-42. PubMed ID: 26659104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment Methodology for Process Validation Lifecycle Stage 3A.
    Sayeed-Desta N; Pazhayattil AB; Collins J; Chen S; Ingram M; Spes J
    AAPS PharmSciTech; 2017 Jul; 18(5):1881-1886. PubMed ID: 27714700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing Cross-Contamination during Lyophilization: GMP and Occupational Cleaning Requirements for Nonproduct and Indirect Product-Contact Parts.
    Denk R; Flückiger A; Kisaka H; Krause S; Maeck R; Restetzki L; Schreiner A; Schulze R
    PDA J Pharm Sci Technol; 2019; 73(5):487-495. PubMed ID: 31420508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals.
    Korakianiti E; Rekkas D
    Pharm Res; 2011 Jul; 28(7):1465-79. PubMed ID: 21161338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.